HB1796: allowing the use of psilocybin in approved clinical settings to treat qualified medical conditions.

Related law links

RSA references from bill data

• 126-X · reference · effective 2027-01-01

  PTER 126-XX THERAPEUTIC USE OF PSILOCYBIN 126-XX:1 Definitions. In this chapter: I. "Board" means the psilocybin production establishment licensing board created pursuant to RSA 126-XX:7. II. "Provider" means an approved medical or therapy provider licensed in this state who also holds a license from the department to recommend or provide services to qualified patients. III. "Department" means th

• 318-B · reference · effective 2027-01-01

  arch, or arrest of a person or for a violation of probation or parole, and psilocybin that relates to the conduct is not contraband or subject to seizure or forfeiture pursuant to RSA 318-B: (a) A cultivator or provider possessing or transporting not more than an adequate supply of psilocybin for medical purposes as defined by department rule; and (b) A provider administering or a qualified patient t

• 326-B · reference · effective 2027-01-01

  rgeon or osteopathic physician and surgeon licensed pursuant to RSA 329, a physician associate licensed pursuant to RSA 328-D, or an advanced practice registered nurse pursuant to RSA 326-B, who is registered by the department to recommend treatment with psilocybin. XX. “Qualified therapy provider” means a physician and surgeon or osteopathic physician and surgeon licensed pursuant to RSA 329, a physic

• 328-D · reference · effective 2027-01-01

  . “Qualified medical psilocybin provider” means a physician, surgeon or osteopathic physician and surgeon licensed pursuant to RSA 329, a physician associate licensed pursuant to RSA 328-D, or an advanced practice registered nurse pursuant to RSA 326-B, who is registered by the department to recommend treatment with psilocybin. XX. “Qualified therapy provider” means a physician and surgeon or osteopat

• 329 · reference · effective 2027-01-01

  individual is authorized to act as an agent. XIX. “Qualified medical psilocybin provider” means a physician, surgeon or osteopathic physician and surgeon licensed pursuant to RSA 329, a physician associate licensed pursuant to RSA 328-D, or an advanced practice registered nurse pursuant to RSA 326-B, who is registered by the department to recommend treatment with psilocybin. XX. “Qualified thera

• 329-B · reference · effective 2027-01-01

  geon licensed pursuant to RSA 329, a physician associate licensed pursuant to RSA 328-D, an advanced practice registered nurse under RSA 326-B, a psychologist licensed pursuant to RSA 329-B, or a social worker licensed pursuant to RSA 330-A, who is registered by the department to administer treatment with psilocybin. XXI. “Qualified therapy provider agent” means an individual who holds a valid qualified

• 330-A · reference · effective 2027-01-01

  ciate licensed pursuant to RSA 328-D, an advanced practice registered nurse under RSA 326-B, a psychologist licensed pursuant to RSA 329-B, or a social worker licensed pursuant to RSA 330-A, who is registered by the department to administer treatment with psilocybin. XXI. “Qualified therapy provider agent” means an individual who holds a valid qualified therapy provider agent registration card. XXII.

• 541-A · reference · effective 2027-01-01

  chapter or grounds for revocation. III. The licensee pays a renewal fee as determined by the department by rule. 126-XX:9 Reporting. The commissioner shall adopt rules under RSA 541-A for the collection of data from cultivators, providers, and qualified patients as a means to evaluate the efficacy of the medical use of psilocybin and publish an annual assessment of the program. The assessment shall

• 6:12 · amend · effective 2027-01-01

  s findings and recommendations, within 180 days of the effective date of this chapter. 4 New Subparagraph; Application of Receipts; Therapeutic Psilocybin Treatment Fund. Amend RSA 6:12, I(b) by inserting after subparagraph (410) the following new subparagraph: (411) Moneys deposited in the therapeutic psilocybin treatment fund as established in RSA 126-XX:11. 5 Effective Date. This act shall ta

RSAs mentioned by this document

• RSA 6 · STATE TREASURER AND STATE ACCOUNTS
• RSA 126-X · USE OF CANNABIS FOR THERAPEUTIC PURPOSES
• RSA 318-B · CONTROLLED DRUG ACT
• RSA 326-B · NURSE PRACTICE ACT
• RSA 328-D · PHYSICIAN ASSOCIATES
• RSA 329 · PHYSICIANS AND SURGEONS
• RSA 329-B · PSYCHOLOGISTS
• RSA 330-A · MENTAL HEALTH PRACTICE
• RSA 541-A · ADMINISTRATIVE PROCEDURE ACT
• RSA 6:12 · Application of Receipts